



The Digital Examiner

www.prostaidcalgary.org

269 March 2022

“Our life is March weather; savage and serene in the same hour .”

Ralph Waldo Emerson

Connect with us:

Information

Phone: 403-455-1916
info@prostaid.org

Brad Sterling President

president@prostaid.org

Support Groups

Frank Altin Warriors

faltin@telusplanet.net

Wives, Partners & Caregivers

info@prostaid.org

Newly Diagnosed

info@prostaid.org

Mailing Address

PROSTAID Calgary Society

PO Box 72126
RPO Glenmore Landing
Calgary, Alberta
T2V 5H9
Phone: 403-455-1916

To subscribe to The Digital Examiner

info@prostaid.org

PROSTAID Calgary is self-funded.

[Click here to help us
to continue our
good work by
donating on-line](#)

Next General Meeting:
Tuesday, March 8th, 2022 @ 7:15 pm
via ZOOM
**“On the PREVENT Study and OPEN
MIC Night”**
Please RSVP to program.director@prostaid.org



Dr. Philip Barber, Neurologist—

Dr. Philip A. Barber is an Associate Professor of Neurology in the Department of Clinical Neurosciences at the University of Calgary where he co-directs the Stroke Prevention Clinic

and is a member of the Calgary Stroke Program.

Dr. Barber’s major interests are dementia and stroke. As the Principal Investigator of the PREVENT study, Dr. Barber aims to detect dementia in subjects at risk of the condition many years before it develops. By taking this approach, we hope to be able to do something about it at the earliest opportunity.

Dr. Barber enjoys the outdoors with his family during his free time. He is usually so invested in his work that he forgets to switch on his office lights after sunset and works in the dark, using his laptop as the only source of light!

“OPEN MIC NIGHT” will immediately follow the presentation.

Side Bar:



Our March general meeting will be a slightly different format than usual. We are going to try an “Open Mic” night where we hope to hear from members about things that are important to you; when to start face-to-face meetings again? Suggestions for new location of the meetings? Changes wanted to DE? Topics of interest for guest speakers? It will be very informal, so take yourself OFF mute and tell us what you think.

- * Dr. Philip Barber will be doing a short presentation on the PREVENT Study he is leading. See some details on Page 2.
- * On Page 3 I have included a link to an article that answers a question raised at the February meeting about new technology coming to the Cancer Centre when it opens next year.
- * I have also included direct links to some open research surveys that pay honorariums.

Stay healthy,
Dorothy

Dorothy Rodehutsors
Program Director

What's new in RESEARCH:

What's new in this month:

The PREVENT Study

Editor's note: Here is a study that may interest you. While it is not part of our usual prostate cancer and related topics, it is useful from a dementia perspective and how your participation can contribute to this research.

What is the PREVENT study?

The Predementia Neuroimaging of Transient Ischemic Attack (PREVENT) study is a longitudinal study that is carried out at the Foothills Hospital in Calgary.

This study is looking for men aged 60-75 years. The goal of PREVENT is to help doctors diagnose dementia sooner by using repeated magnetic resonance imaging (MRI). Late-life dementia often begins many years before symptoms are detected. Therefore, the purpose of the study is to identify biomarkers that can predict patients who are at a high risk of developing dementia before they show signs of cognitive decline.

In addition to healthy controls, we recruit patients who have had a transient ischemic attack (TIA) because studies have now shown that patients with TIA have a 4-fold increase in late-life dementia. (A TIA, sometimes called a mini-stroke, is a temporary blockage of blood flow to the brain). Therefore, TIA patients are an understudied group of patients who are suitable for the study of dementia.

I am interested in participating, but what would I have to do as part of the study?

You would be participating in the study as a healthy control who have not had a TIA. We are going to compare data from the TIA patients and healthy controls to better understand the causes of dementia.

If you agree to participate in this study and you meet all the entry criteria, the study doctor will collect information from you and will review your health records, and access your medical history and blood parameters such as random and fasting glucose, lipid profile as part of the study.

The researcher, Dr. Philip Barber will be speaking at our Tuesday March 8th meeting at 7:15 PM for those interested to learn more. I have just concluded my five (5) years participation and sincerely recommend you give it your consideration. David Lunn, Past President, PROSTAID Calgary. dlunn@shaw.ca

[PROpel Suggests Adding Olaparib to Abiraterone Improves Outcomes in Castration-Resistant Prostate Cancer Regardless of Homologous Recombination Repair Status](#)

- * Adding olaparib to abiraterone therapy improves outcomes in patients with castration-resistant metastatic prostate cancer, regardless of homologous recombination repair (HRR) status, according to results of PROpel, presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, which took place here and online from February 17 to 19.
- * February 2022

[Phase 1 Study of PSCA-Targeted Chimeric Antigen Receptor \(CAR\) T Cell Therapy for Metastatic Castration-Resistant Prostate Cancer \(mCRPC\)](#)

- * Chimeric antigen receptor (CAR) T cell therapies are in development for metastatic castration-resistant prostate cancer. These engineered T-cells are genetically altered to have receptors that recognize a tumor specific protein as well as a co-stimulatory molecule.
- * February 2022

[Active Surveillance for Patients with Intermediate-Risk Disease: Risk vs. Benefit](#)

- * The 2022 GU ASCO Annual meeting included a session on the optimization management of localized prostate cancer, specifically looking at artificial intelligence (AI), active surveillance, and intervention, featuring a presentation by Dr. Stacy Loeb discussing active surveillance for patients with intermediate risk disease.
- * February 2022

Articles of Interest:

Everyone:

For Newly Diagnosed:

Guideline Review on Prostate Cancer - Epidemiology, Initial Diagnosis, and Life Expectancy of Men With Prostate Cancer

- * Dr. Klaassen provides an overview of prostate cancer epidemiology, details the initial prostate cancer diagnosis, and highlights the importance of estimating life expectancy in these patients. Christopher Wallis continues discussing these topics and aligns them with the recommendations from the NCCN Guidelines.
- * November 2021

PSMA-Targeted PET Imaging and Interpretation: What Urologists Need to Know

- * This presentation by Drs. Michael Gorin and Steven Rowe, provides a thorough, comprehensive overview of PSMA-targeted PET Imaging within the field of urology, with an emphasis on what Urologists need to know. While the focus is primarily on prostate cancer, they do briefly touch on the role of this novel technology for non-prostate malignancies.
- * September 2021

Article related to question from February meeting:

Calgary to build cyclotron for radiopharmaceuticals

- * Alberta is committing more than \$18 million over the next three years to build Calgary's first cyclotron and a new radiopharmaceutical facility. The funding is a part of the government's \$3.4-billion plan to build new health facilities, equipment and information systems across the province
- * July 2021

Molecular Imaging and Targeted Radionuclide Therapy with PSMA Radiopharmaceuticals

- * A discussion on the role of molecular imaging and targeted radionuclide therapy using PSMA-based radiopharmaceuticals. Included is a disease overview to contextualize the role of advanced imaging. Presenter emphasized that prostate cancer begins to grow, with an increasingly large tumor volume leading up to initial diagnosis which is followed by curative-intent treatment.
- * October 2021

Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. - Beyond the Abstract

- * The urological community has the obligation to grasp every means to reduce mortality from urological cancers. Prostate cancer is the most frequent male cancer and is the second most lethal cancer in men in an increasing number of countries. The disease has a particularly long palliative period with a huge impact on quality of life and healthcare costs.
- * October 2021



Other News:

EVENT/Research Studies:

PCa Research Studies looking for participants:

Just quickly letting you know about a few research studies that you may distribute to anyone who is interested:

- * Re: metastatic PCa – 30 min online survey with \$75 honorarium. [Click here.](#)
- * Re: physical activity, cancer, and COVID-19—brief online survey. [Click here.](#)
- * Re: metastatic PCA—30 min phone interview with \$75 honorarium. [Click here.](#)
- * Exploring psychosocial well-being, physical activity, and comfort gathering among adults affected by cancer in the context of COVID-19—brief online survey. [Click Here](#)
- * Side effects/impacts on QOL of metastatic prostate cancer treatment and disease symptoms – 30 min online survey with \$75 honorarium . [Click Here](#)

Clinical Trials:

[Anticipated Data from Transformative Trials at ASCO GU 2022](#)

- * Discussion about the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium on Feb 17-20, 2022, and the data from key presentations in prostate cancer, bladder cancer, and kidney cancer.
- * January 2022



Videos:

[The History of Radiopharmaceuticals in Prostate Cancer](#)

- * A conversation on the history of radiopharmaceuticals, their development, and where they may ultimately fit in the prostate cancer treatment landscape.
- * December 2021

[Cognitive Assessment in Men with Metastatic Castrate-Resistant Prostate Cancer \(mCRPC\) Randomly Receiving Darolutamide or Enzalutamide in the ODENZA Trial](#)

- * Discussing the 2021 European Society for Medical Oncology (ESMO) presentation of the results from the ODENZA trial comparing darolutamide and enzalutamide, with a focus on cognitive assessment.
- * October 2021

[Trials and Tribulations in the Management of Metastatic Hormone-Sensitive Prostate Cancer](#)

- * While treatment with androgen deprivation therapy (ADT) provides initial responses, progression is common and a large proportion of prostate cancer-related deaths occur among men initially diagnosed with metastatic disease.
- * December 2021

PROSTAID Calgary On-Line



Thank you to our Sponsors and Community Partners

